All articles tagged with #pharma tariffs
The Trump administration has delayed implementing 100% tariffs on pharmaceuticals, which were initially threatened to start immediately, signaling a shift towards encouraging voluntary commitments from drug companies to invest in U.S. infrastructure and negotiate drug prices.
President Trump's announcement of a 100% tariff on foreign brand-name drugs raises questions about which drugs will be affected, potential price increases for patients, the impact on U.S. drug manufacturing, and the risk of shortages, with many uncertainties about exemptions and the timeline for manufacturing changes.
The U.S. plans to impose 100% tariffs on imported branded pharmaceuticals, potentially raising drug prices, but exemptions for generics and U.S.-based manufacturing facilities may limit the impact. Major drugmakers are stockpiling supplies in anticipation, and some European companies expect little to no effect due to existing manufacturing investments and trade agreements.
Merck is acquiring Verona Pharma for $10 billion to strengthen its lung-disease portfolio, while U.S. political developments threaten to impact drugmakers through potential high tariffs and Medicaid funding cuts, notably affecting companies like Gilead and Vertex. Additionally, new clinical trials are underway for gene therapies targeting muscle-wasting diseases, and Gilead has committed to providing its HIV prevention drug to millions in low-income countries at no profit.